^
Association details:
| Biomarker: | JAK3 M511I |
|---|---|
| Cancer: | T Acute Lymphoblastic Leukemia |
| Drug: | Xeljanz XR (tofacitinib XR) (JAK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model
Excerpt:
...the proliferation of the JAK3 M511I mutant T-ALL cells was inhibited by tofacitinib or ruxolitinib, whereas the proliferation of human T-ALL cells that did not express mutant JAK3 were not affected by the presence of JAK inhibitors (Figure 5B).
DOI:
https://doi.org/10.1182/blood-2014-04-566687
